• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Pfizer
Biotech

Pfizer cans twice-daily oral obesity program

Months after making twice-daily danuglipron its top prospect, Pfizer has dropped the program after 50%+ of patients dropped out of a midphase trial.
Nick Paul Taylor Dec 1, 2023 8:30am
WCG Clinical Inc
Sponsored

Ethics, Regulations, and Operations of Pediatric CGT Trials

Nov 27, 2023 8:00am
cough quarantine COVID sick cold flu

After Merck's cough drama, GSK knew what to do with Bellus asset

Nov 30, 2023 8:00am
syringes

FDA recommends avoiding plastic syringes made in China

Dec 1, 2023 11:47am
merger acquisition deal

Concentra back with another buyout offer, this time for LianBio

Dec 1, 2023 11:03am
Cleveland Clinic Canon RSNA imaging partnership

Cleveland Clinic, Canon collab on imaging research center

Dec 1, 2023 10:12am
CRO News

Merck turns to Acclinate to boost diversity of cancer trials

Nov 30, 2023 8:58am

QuantHealth debuts AI-based program to simulate trials at scale

Nov 29, 2023 10:31pm

RetinAI Medical joins non-profit macular degeneration initiative

Nov 29, 2023 11:36am

BioVie blames trial sites for phase 3 Alzheimer’s drug fail

Nov 29, 2023 10:05am
See More CRO News
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy